ascopubs.org

A double-blind, randomized, placebo-controlled, parallel study to investigate the auxiliary effects of fucoidan in patients with locally advanced rectal cancer who receive ...

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. This is an ASCO Meeting Abstract from the 2023 ...
BMJ Global Health

Impact of cooking with liquefied petroleum gas compared with traditional cooking practices on perinatal and early neonatal mortality: the Poriborton cluster randomis…

Objective To determine whether liquefied petroleum gas (LPG) can reduce perinatal mortality in a setting with high reliance ...
Business Wire

Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial

ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s ...

Bayer’s Finerenone CKD Trial Completion: What Investors Should Watch Next

A positive finerenone readout in non-diabetic CKD would extend Bayer’s cardiorenal franchise beyond current diabetic CKD use, supporting sentiment for BAYRY by opening a broader addressable market. It ...
ascopubs.org

Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

This randomized, parallel-group, phase II study included a safety run-in and a subsequent randomized phase. Eligible patients (cT3N+M0 or cT4NanyM0) received long-course nCRT (45-50.4 Gy in 25-28 ...
The New England Journal of Medicine

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of ...
The New England Journal of Medicine

Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU

Randomized, controlled trials have shown both benefit and harm from tight blood-glucose control in patients in the intensive care unit (ICU). Variation in the use of early parenteral nutrition and in ...